New Delhi, July 26 (IANS) Japanese researchers have found a promising new target for treating Multiple Sclerosis (MS) — a chronic disease of the central nervous system.
The study by researchers at Kyushu University, Japan highlights a channel protein, connexin 43 (Cx43), as a potential therapeutic target for managing chronic MS symptoms.
In an experimental mouse model of MS, the researchers discovered that blocking Cx43 with an inhibitor called INI-0602 significantly improved symptoms.
“Our findings suggest that targeting Cx43 could serve as a novel therapeutic strategy for chronic MS,” said lead author Ryo Yamasaki, Associate Professor at Kyushu University.
“This, in turn, could facilitate the development of new treatments for patients with MS”, said Professor Yamasaki, in the paper published in Scientific Reports.
MS is a debilitating condition where the immune system attacks the central nervous system, causing damage to the myelin sheath that protects nerve fibres.
This leads to demyelination and the formation of lesions, resulting in severe neurological symptoms.
Current treatments for chronic MS are limited, prompting the search for new therapeutic avenues.
The study focused on astroglia, supportive cells in the brain that overproduce Cx43 in MS patients.
This overproduction releases pro-inflammatory chemicals, triggering harmful immune responses that exacerbate neuron damage.
The researchers used INI-0602 to block Cx43 channels, which suppressed the protein’s overproduction and reduced hallmark MS features, including demyelination and excessive immune cell infiltration.
The research team also observed that INI-0602 reduced pro-inflammatory cytokines and increased anti-inflammatory cytokines in cerebrospinal fluid, alleviating disease severity.
These results suggest that INI-0602 could modulate immune processes and reduce neuroinflammation, providing a new approach to MS treatment.
While these findings are promising, the researchers caution that animal models have limitations, although the study could pave the way for more effective treatments, offering hope for improved management of chronic neurological conditions.
–IANS
ts/rvt/rad
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
